Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic compound, synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed.
It is described as an angiogenesis inhibitor, antiangiogenic agent, with about two orders of magnitude greater potency (pharmacology), potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate.
FMPA showed about the same affinity (pharmacology), affinities for the progesterone receptor, progesterone and glucocorticoid receptors as MPA.
It reached the preclinical research, preclinical phase of research prior to the discontinuation of its development.
See also
* Anecortave acetate
References
External links
Fluoromedroxyprogesterone acetate (FMPA) - AdisInsight
Abandoned drugs
Acetate esters
Angiogenesis inhibitors
Drugs with unknown mechanisms of action
Experimental cancer drugs
Glucocorticoids
Pregnanes
Progestogen esters
Progestogens
{{Antineoplastic-drug-stub